NeuCyte is a biotechnology company focused on CNS drug discovery. Based on its proprietary SynFire®technology for generating human iPSC-derived neural cells, NeuCyte has developed relevant functional human cell-based platforms for target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling. The team is actively pursuing drug discovery programs for Alzheimer disease, ALS, Epilepsy, Fragile X Syndrome and more.